Mission: Cure’s webinar on February 23rd, 2022 featured three biotech executives who are searching for a cure for pancreatitis and one of its major complications, diabetes.

John Mellnik, CEO of Path BioAnalytics (PBA), discusses their most recent project that uses translational science and proprietary technology to identify drugs that will correct the problems in the pancreas caused by mutations in the CFTR gene.

Dena Cohen and Tony Kolton, CSO and CEO of Regenerative Medical Solutions (RMS), discuss their personalized cell-based therapy to cure diabetes. Pancreatitis patients who undergo TPIAT may develop insulin dependence, and RMS’s patented technology will use the patient’s own cells to avoid the need of immunosuppressants that current transplants require.